Award of Options by CEO to CFO and General Counsel

RNS Number : 5759Q

Ergomed plc

30 November 2016

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Award of options by Chief Executive Officer over personally owned shares to

Chief Financial Officer and General Counsel

London UK 30 November 2016:  Ergomed plc ("Ergomed" or the "Company", LSE: ERGO), a pharmaceutical services and drug development company, today announces that Dr Miroslav Reljanović, founder and Chief Executive Officer of Ergomed, has granted options over 250,000 ordinary shares from his personal holding to Stephen Stamp, Chief Financal Officer and Sanja Jurić, General Counsel as follows:

Name	No. of options	Exercise Price	Vesting	Resulting interest in options	Current shareholding in the Company
Stephen Stamp	100,000	£0.01	50% 11 January 2017 50% 11 January 2018	500,000	200,000
Sanja Jurić	150,000	£0.01	50% 30 November 2016 50% 30 November 2017	300,000	NIL

The 250,000 ordinary shares over which Dr Reljanović has granted options will remain in his personal holding until exercise. Dr Reljanović is interested in 17,632,237 ordinary shares of the Company, representing 43.53% of the issued share capital.

- ENDS -

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanovic (Chief Executive Officer)
Stephen Stamp (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
Stifel Nicolaus Europe Limited	Tel: [phone]
Jonathan Senior (Joint Broker)
FTI Consulting - for UK enquiries	Tel: [phone]
Simon Conway / Mo Noonan
MC Services AG - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

 

END

 

 

DSHUROORNRAAOAA